Source comparison
Tesamorelin vs CJC-1295/Ipamorelin
CJC-1295 (with DAC) is a modified GHRH analog with a dramatically longer half-life (5 to 8 days) due to its Drug Affinity Complex. It is often combined with ipamorelin, a growth hormone-releasing peptide (GHRP) that acts on ghrelin receptors rather than GHRH r
This comparison does not assign a generated winner or score.
- CJC-1295 (with DAC) is a modified GHRH analog with a dramatically longer half-life (5 to 8 days) due to its Drug Affinity Complex. It is often combined with ipamorelin, a growth hormone-releasing peptide (GHRP) that acts on ghrelin receptors rather than GHRH receptors.
- GHRH receptor agonist
- GHRH + ghrelin receptor agonist
- Half-life
- ~26 minutes
- CJC: 5-8 days; Ipamorelin: ~2 hours
- GH release pattern
- Single pulsatile burst
- Sustained elevation (CJC) + pulse (Ipa)
- FDA approval
- Yes (for HIV lipodystrophy)
- No
- Clinical trial data
- Phase 3 (800+ participants)
- Limited human data
- Visceral fat data
- 15-18% reduction (CT-verified)
- No CT-verified fat loss data
- Typical dose
- 2 mg/day SC
- CJC: 2 mg/week; Ipa: 200-300 mcg 2-3x/day
- Cost (approximate)
- The critical advantage of tesamorelin is evidence quality. Its visceral fat reduction was measured by CT scan in randomized, placebo-controlled trials with hundreds of participants. CJC-1295/ipamorelin has anecdotal support and small studies but nothing approaching that level of evidence (Ionescu & Bhatt, Expert Opin Biol Ther 2015).
- The critical advantage of CJC-1295/ipamorelin is cost. It runs roughly one-third the monthly price of tesamorelin at research-grade pricing. For users prioritizing affordability over evidence certainty, the combination is a practical alternative.